Free CME

Faculty discusses the prevention and management of cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and infections in patients with relapsed/refractory multiple myeloma treated with BCMA-directed bispecific antibodies.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Evaluate the benefits of newly available anti-VEGF treatment options for DR and DME that may improve visual outcomes.
Discuss effects of delayed and interrupted treatment for DME.

This accredited activity reviews advancements in lung transplant surgery, with a focus on robotic lung transplant and ex vivo lung perfusion.

Listening First: Shared Decisions That Build Trust in Pediatric Obesity Care is a CME activity designed to support pediatricians in delivering effective, evidence-based care to children and adolescents with obesity. Despite the growing prevalence and risks of pediatric obesity, many clinicians face barriers such as limited training, low confidence, and discomfort initiating sensitive conversations.

This activity provides practical guidance on guideline-recommended screening, culturally and developmentally appropriate communication strategies, and the development of individualized treatment plans. With a focus on shared decision-making and building trust with families, participants will gain the tools needed to improve patient engagement and outcomes in pediatric obesity care.

Meet a 52-year-old woman with type 2 diabetes and hypertension whose recent laboratory results reveal a decline in kidney function. How would you manage this patient? In this 15-minute activity, read about next steps in the management of advanced kidney disease.

The integration into practice of sustained delivery devices and therapies that offer longer duration of action have further revolutionized the management of patients with diabetic macular edema (DME). However, selecting patients who will optimally benefit from these newer therapies can be challenging. Biomarkers of vascular instability are emerging, which could help guide treatment decisions and provide useful tools for monitoring disease control. This CE activity utilizes Curbside Consults, a dynamic and interactive case-based platform that will highlight these therapeutic strategies for the management of DME that reduce dosing frequency and enhance anatomic outcomes. Experts in the field also review the role of novel biomarkers to guide early clinical decision-making and evaluate treatment options for patients with DME based on the latest clinical evidence.

Hear from a panel of clinicians from community practices about their experiences, including the challenges and successes, with integrating B-cell maturation antigen (BCMA)-directed bispecific antibodies into their practices. Explore patient management strategies for bispecific antibodies, from starting treatment at a community center to providing long-term care after treatment initiation at either a community or tertiary center.

Explore recent findings in Pain Reprocessing Therapy with Yoni K. Ashar, PhD. This free lecture connects emerging research with assessment, patient education, and treatment planning for chronic pain.

Discuss consequences of delayed or inter­rupted treatment for nAMD
Describe efficacy and safety of newer anti-VEGF treatments for nAMD
Jointly provided by Partners for Advancing Clinical Education and DKBmed, LLC

Type 2 diabetes (T2D) rarely travels alone. Most patients carry overlapping cardiovascular, renal, and metabolic (CKM) risk, and this convergence is now central to how T2D should be managed, not a comorbidity footnote. Despite clear guideline recommendations, GLP-1 RAs and dual GIP/GLP-1 RAs with proven cardiovascular and renal benefit remain underused among patients who stand to gain the most. Patient complexity, an expanding evidence base for outcomes, and persistent clinical inertia all contribute to this gap.

Endocrinologists, endocrinology NPs and PAs, and the broader care team are positioned to close it. This training program, modeled on the CDC Training of Trainers approach, equips endocrinology-led teams to build CKM risk into everyday T2D decision-making: selecting and sequencing GLP-1-based therapies according to a patient’s cardiovascular, renal, and metabolic profile, not glycemic control alone. The content also addresses related benefits emerging in this drug class, including MASH and OSA, within the broader CKM framework.Designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025
Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.

Upon completion of this activity, learners will be able to:

• Implement routine OSA screening for patients with obesity and other OSA risk factors.
• Identify tools that can aid in screening patients for OSA.
• Initiate diagnostic workups for patients with suspected OSA.
• Evaluate results from OSA diagnostic studies.
• Implement multidisciplinary approaches to formulate tailored management strategies for OSA that account for patient preferences and new therapeutic options.

In this online, self-learning activity:

Osteoporosis in aging men is a growing public health problem yet remains under-recognized in primary and specialty care. Population-based cohorts show that adults aged ≥80 years now account for most hip fractures, and in this age group men experience higher perioperative morbidity and mortality than women at comparable ages. Contemporary US trend analyses confirm a high and in some groups increasing prevalence of osteoporosis and low bone mass among adults ≥50 years, with substantial burden among older men. Health-economic models and actuarial reports estimate more than two million osteoporotic fractures annually in the United States, costing about $17 billion in 2005 and rising to an estimated $57 billion over the past two decades, with further growth expected by 2040; men already account for more than one-quarter of this burden. Prospective outcomes work from the ICUROS US study and Medicare claims analyses underscores prolonged quality-of-life loss and markedly higher all-cause costs after fragility fractures, especially hip and vertebral fractures in older adults, including men.

Bronchiectasis is a complex and increasingly prevalent condition often overlooked in clinical practice, with frequent overlap with other respiratory diseases such as COPD and asthma. Persistent airway inflammation, chronic infection, and mucociliary dysfunction drive disease progression, leading to significant morbidity and healthcare burden. As the clinical burden of bronchiectasis becomes increasingly recognized, there is an urgent need to better understand the underlying mechanisms of neutrophilic inflammation, alongside efforts to improve early diagnosis and explore current and emerging treatment options that target this vicious cycle.

In this activity, a panel of leading pulmonologists tackle the evolving challenges and emerging opportunities in bronchiectasis management. From diagnostic workup to airway clearance and exacerbation control, the discussion will blend expert insight with real-world clinical scenarios and patient perspectives.
Endocrinologists, endocrinology NPs and PAs, and the broader care team are positioned to close it. This training program, modeled on the CDC Training of Trainers approach, equips endocrinology-led teams to build CKM risk into everyday T2D decision-making: selecting and sequencing GLP-1-based therapies according to a patient’s cardiovascular, renal, and metabolic profile, not glycemic control alone. The content also addresses related benefits emerging in this drug class, including MASH and OSA, within the broader CKM framework.Designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025
Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.

In this online, self-learning activity:

Neonatal respiratory distress syndrome (nRDS) remains a leading cause of respiratory failure and morbidity among preterm infants worldwide, despite major advances in antenatal steroids, continuous positive airway pressure (CPAP), and surfactant therapy. Contemporary guidelines emphasize early noninvasive respiratory support from birth, selective surfactant rescue once CPAP begins to fail, and structured, protocolized care across gestational age strata. Yet practice-pattern studies across high- and middle-income settings show wide variation in initial respiratory support, surfactant thresholds, and use of minimally invasive techniques, with extremely preterm and late preterm infants often receiving care that diverges from guideline-concordant pathways. These inconsistencies increase cumulative ventilator exposure and risk of bronchopulmonary dysplasia (BPD) and other complications, underscoring a persistent implementation gap between best evidence and routine NICU care.

This MedHive™ educational initiative focuses on empowering endocrinologists to deliver personalized, evidence-based care for patients with type 2 diabetes. Through interactive peer discussions and expert insights, participants will contribute their collective knowledge to explore strategies to optimize therapy selection, improve adherence, and achieve both glycemic and extra-glycemic goals aligned with the latest 2025 ADA Standards of Care.

This activity is supported by educational grants from Genetech and Regeneron Pharmaceuticals Inc.
Discuss consequences of delayed or inter­rupted treatment for nAMD
Describe efficacy and safety of newer anti-VEGF treatments for nAMD

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment presented at the HFSA Annual Scientific Meeting 2025 and AHA Scientific Sessions 2025.

Despite major therapeutic advances, diabetic macular edema (DME) remains a leading cause of vision loss in adults with diabetes, with delayed diagnosis, treatment burden, and suboptimal responses continuing to challenge real-world outcomes. Although intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the established first-line standard of care, many patients experience persistent or refractory DME, and long-term visual gains in routine practice often fall short of results seen in clinical trials due to undertreatment and adherence challenges. Early identification of inadequate treatment response and timely therapy modification are critical, as untreated or insufficiently treated DME can result in significant, irreversible vision loss. Emerging evidence supports the use of newer anti-VEGF agents with extended dosing intervals, as well as the early integration of corticosteroid implants for patients with suboptimal responses. Corticosteroid therapies offer broad anti-inflammatory benefits and have demonstrated meaningful visual and anatomical improvements, particularly when introduced earlier in the disease course. In this CE Snips activity, expert faculty assess how to recognize when patients with DME demonstrate insufficient response to anti-VEGF therapy and when to integrate corticosteroid therapy based on current clinical evidence and real-world data.

Patient advocate and HealthTree Foundation CEO Jenny Ahlstrom shares fresh survey insights into the physical, emotional, and social quality-of-life experiences of patients treated with bispecific antibodies, while spotlighting key educational, financial, and community resources designed to support them.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

In this brief 15-minute activity, you will:

– Follow the case of a patient who presents with foot drop and no other medical conditions
– Choose optimal management approaches by answering nongraded questions within the activity (answers are collected for informational purposes only and used to assess the effectiveness of this educational activity)
– See how your answers compare with those of your peers
– View video clips providing expert insights